Covered recipient · General Payments record
MICHAEL GOLD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$142,747.23
186 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $93,490.95 | 30 |
| Grant | $33,750.00 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,650.00 | 3 |
| Food and Beverage | $4,794.34 | 138 |
| Travel and Lodging | $3,182.57 | 5 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,740.00 | 1 |
| Education | $139.37 | 7 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL GOLD
NPI 1073549176 · CMS profile ID 48145
NASHVILLE, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL GOLD, NPI 1073549176, CMS profile ID 48145. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). MICHAEL GOLD, NPI 1073549176, CMS profile ID 48145. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- MICHAEL GOLD, NPI 1073549176, CMS profile ID 48145, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 186 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1073549176?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
186 matching records · $142,747.23 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 186.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $3,560.00 | 09/13/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047735 | CMS |
| ABBVIE INC. | $1,780.00 | 09/13/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047737 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27.64 | 09/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887336065 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $10.48 | 09/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947509441 | CMS |
| GENZYME CORPORATION | $25.27 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938792905 | CMS |
| E.R. Squibb & Sons, L.L.C. | $26.46 | 09/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932583653 | CMS |
| Almirall LLC | $16.93 | 09/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965163221 | CMS |
| Almirall LLC | $55.68 | 09/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965163223 | CMS |
| Novartis Pharmaceuticals Corporation | $22.35 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893704267 | CMS |
| PFIZER INC. | $2.53 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949566713 | CMS |
| ABBVIE INC. | $20.74 | 08/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047733 | CMS |
| Allergan, Inc. | $149.80 | 08/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 889895837 | CMS |
| Allergan, Inc. | $33.38 | 08/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 889895833 | CMS |
| Allergan, Inc. | $1,290.50 | 08/26/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 889895835 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $13.27 | 08/24/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947509433 | CMS |
| Genentech USA, Inc. | $18.99 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950764561 | CMS |
| ABBVIE INC. | $21.79 | 08/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047731 | CMS |
| STRATA Skin Sciences, Inc. | $775.00 | 08/12/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 964161702 | CMS |
| Allergan, Inc. | $2,225.00 | 08/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 889895831 | CMS |
| Allergan, Inc. | $43.91 | 08/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 889895829 | CMS |
| Galderma Laboratories, L.P. | $73.01 | 08/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 952273761 | CMS |
| Solta Medical, a division of Bausch Health US, LLC | $2,610.00 | 08/02/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941783119 | CMS |
| ABBVIE INC. | $26.62 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047729 | CMS |
| MAYNE PHARMA INC. | $15.69 | 08/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 959836339 | CMS |
| Allergan, Inc. | $13.72 | 07/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 889895827 | CMS |
| ABBVIE INC. | $17.41 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047727 | CMS |
| GENZYME CORPORATION | $128.58 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938792893 | CMS |
| ABBVIE INC. | $15.97 | 07/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047725 | CMS |
| ABBVIE INC. | $24.32 | 07/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047723 | CMS |
| PFIZER INC. | $21.17 | 07/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949616357 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $20.56 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947509431 | CMS |
| Merz North America, Inc. | $37.69 | 07/17/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950342313 | CMS |
| Merz North America, Inc. | $466.56 | 07/14/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950342311 | CMS |
| Merz North America, Inc. | $2,529.19 | 07/13/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950342309 | CMS |
| Merz North America, Inc. | $132.20 | 07/13/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950342315 | CMS |
| Novartis Pharmaceuticals Corporation | $12.56 | 07/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893704256 | CMS |
| Solta Medical, a division of Bausch Health US, LLC | $2,610.00 | 07/12/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941783111 | CMS |
| PFIZER INC. | $6.05 | 07/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949607173 | CMS |
| Lumenis BE (HK) Limited | $1,025.00 | 06/30/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942794139 | CMS |
| Solta Medical, a division of Bausch Health US, LLC | $435.00 | 06/30/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941783127 | CMS |
| Novartis Pharmaceuticals Corporation | $11.93 | 06/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893704253 | CMS |
| PFIZER INC. | $1.43 | 06/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949636929 | CMS |
| Solta Medical, a division of Bausch Health US, LLC | $1,740.00 | 06/23/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941783123 | CMS |
| Solta Medical, a division of Bausch Health US, LLC | $1,740.00 | 06/23/2022 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941783143 | CMS |
| ABBVIE INC. | $24.76 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047721 | CMS |
| ABBVIE INC. | $14.64 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047719 | CMS |
| ABBVIE INC. | $6.96 | 06/10/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047717 | CMS |
| Allergan, Inc. | $1,780.00 | 06/09/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 889895825 | CMS |
| ABBVIE INC. | $28,750.00 | 06/07/2022 | Grant | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891047715 | CMS |
| Novartis Pharmaceuticals Corporation | $12.56 | 06/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893704249 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $373,719.62 | 46 |
| PY2024 | Recipient | $1,007.07 | 3 |
| PY2024 | Principal investigator | $326,767.50 | 36 |
| PY2023 | Principal investigator | $698,835.45 | 48 |
| PY2022 | Principal investigator | $1,057,457.10 | 60 |
| PY2021 | Principal investigator | $1,412,059.53 | 70 |
| PY2020 | Principal investigator | $415,542.55 | 44 |
| PY2019 | Recipient | $27,312.89 | 6 |
| PY2019 | Principal investigator | $430,298.83 | 88 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
46 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $916.68 | 12/31/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202534491 |
| Principal investigator 1 | ABBVIE INC. | $31,356.26 | 12/31/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER LLC | A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation | No dispute reported | 06/30/2026 | 1202534493 |
| Principal investigator 1 | ABBVIE INC. | $6,136.80 | 12/17/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202530992 |
| Principal investigator 1 | ABBVIE INC. | $31,128.10 | 12/17/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1202530994 |
| Principal investigator 1 | Incyte Corporation | $2,173.00 | 12/05/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598157 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 11/19/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598136 |
| Principal investigator 1 | Incyte Corporation | $1,459.50 | 11/19/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598139 |
| Principal investigator 1 | Incyte Corporation | $44.00 | 11/19/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598160 |
| Principal investigator 1 | Incyte Corporation | $44.00 | 11/19/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598164 |
| Principal investigator 1 | ABBVIE INC. | $4,528.20 | 11/13/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202524149 |
| Principal investigator 1 | ABBVIE INC. | $11,203.11 | 11/13/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1202524183 |
| Principal investigator 1 | ABBVIE INC. | $8,137.50 | 11/07/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1202523581 |
| Principal investigator 1 | ABBVIE INC. | $3,513.60 | 11/04/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1202520569 |
| Principal investigator 1 | ABBVIE INC. | $10,553.40 | 10/15/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202516859 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598129 |
| Principal investigator 1 | Incyte Corporation | $1,947.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598132 |
| Principal investigator 1 | Incyte Corporation | $2,800.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598143 |
| Principal investigator 1 | Incyte Corporation | $745.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598148 |
| Principal investigator 1 | Incyte Corporation | $1,775.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598153 |
| Principal investigator 1 | Incyte Corporation | $44.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598168 |
| Principal investigator 1 | Incyte Corporation | $44.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598172 |
| Principal investigator 1 | Incyte Corporation | $1,841.00 | 10/09/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598176 |
| Principal investigator 1 | ABBVIE INC. | $3,513.60 | 10/02/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1202513047 |
| Principal investigator 1 | ABBVIE INC. | $12,050.40 | 09/18/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202511566 |
| Principal investigator 1 | Incyte Corporation | $44.00 | 09/12/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598105 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 09/12/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598108 |
| Principal investigator 1 | Incyte Corporation | $2,033.50 | 09/12/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598111 |
| Principal investigator 1 | Incyte Corporation | $1,947.00 | 09/12/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598118 |
| Principal investigator 1 | Incyte Corporation | $2,800.00 | 09/12/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598120 |
| Principal investigator 1 | ABBVIE INC. | $16,541.40 | 08/14/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202504903 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 08/14/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598101 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 08/14/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240598114 |
| Principal investigator 1 | ABBVIE INC. | $19,617.00 | 07/16/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202498338 |
| Principal investigator 1 | ABBVIE INC. | $16,667.40 | 06/12/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202491189 |
| Principal investigator 1 | ABBVIE INC. | $21,366.00 | 05/16/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202485341 |
| Principal investigator 1 | UCB SA | $197.78 | 04/28/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1246659450 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,910.00 | 04/18/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223278490 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 04/18/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223278492 |
| Principal investigator 1 | ABBVIE INC. | $22,944.60 | 04/16/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202476851 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 04/16/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223278132 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 04/16/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223278134 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 04/16/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223278136 |
| Principal investigator 1 | ABBVIE INC. | $21,996.60 | 03/13/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202463115 |
| Principal investigator 1 | ABBVIE INC. | $18,891.60 | 02/13/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202450942 |
| Principal investigator 1 | ABBVIE INC. | $29,257.32 | 01/16/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202439083 |
| Principal investigator 1 | UCB SA | $43,012.27 | 01/03/2025 | Non-covered Recipient Entity TENNESSEE CLINICAL RESEARCH CENTER | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1246657518 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $1,264.85 | 1 |
| PY2021 | Amount invested | $2,405.00 | 1 |
| PY2021 | Value of interest | $2,107.06 | 1 |
| PY2020 | Amount invested | $2,405.00 | 1 |
| PY2020 | Value of interest | $2,030.16 | 1 |
| PY2019 | Amount invested | $2,405.00 | 1 |
| PY2019 | Value of interest | $1,784.08 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
4 records · PY2019–2022
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2022 | Medimetriks Pharmaceuticals, Inc. | $0.00 | $1,264.85 | Dr. Gold has 1,538 shares at $0.8224 per share. Cert.# (s) 124. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 885344965 |
| PY2021 | Medimetriks Pharmaceuticals, Inc. | $2,405.00 | $2,107.06 | HCP owns 1538 shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 803534827 |
| PY2020 | Medimetriks Pharmaceuticals, Inc. | $2,405.00 | $2,030.16 | Shares of Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 746592327 |
| PY2019 | Medimetriks Pharmaceuticals, Inc. | $2,405.00 | $1,784.08 | Shares of Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 703279847 |